How to Automate CRF Annotations – A Best Practice Guide Blog Post
This free guide explores how to automate CRF annotations, the benefits of automation, and the industry requirements you need to know.
Certara Releases Environmental, Social and Governance Report Blog Post
Report details commitment to understanding, monitoring, and managing social and environmental responsibilities. RADNOR, Pa. — 2024年10月23日 – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in model-informed drug development…
Three Strategies for Navigating the Pharmaceutical Patent Cliff Blog Post
In the pharmaceutical industry, the end of a product’s patent protection, known as the loss of exclusivity (LoE), marks a significant turning point. It’s a period fraught with challenges as…
Why You Need an Integrated Development Plan Blog Post
Learn about the Integrated Development Plan for successful drug development & its relation to the Target Product Profile & Clinical Development Plan.
RAPS Sponsored Webcast: Optimizing Pediatric Oncology Drug Development: A Comprehensive Overview Blog Post
Summary Developing safe and effective oncology medications for children presents unique challenges due to ethical considerations and physiological differences across age groups. Traditional clinical trials often face limitations in sample... Certara Appoints John Reynders as New Independent Board Member Blog Post
ぺンシルベニア州ラドナー：2024年10月16日ーバイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD to its Board of Directors,…
Certara Head of AI Recognized in PharmaVoice 100 Blog Post
Certara’s Senior Vice President, Chris Bouton, Head of Artificial Intelligence recognized for his technical innovation, entrepreneurship, and leadership. RADNOR, Pa. — 2024年10月10日 – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a…
Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024 Blog Post
Radnor, Pa. — October 9th, 2024– Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of…
Toxicology Services and Nonclinical Drug Development Support Page
サターラの毒性学コンサルタントは、規制段階におけるお客様の製品をサポートする、専門的な前臨床安全性コンサルティングサービスを提供しています。
